Larentiinae | Jotup

PrecisionLife and Cyclica Sign Strategic Partnership Combining Leading Data-driven Biology and Chemistry Platforms to Create a Rapid Innovation Engine for Drug Discovery

Retrieved on:

Monday, May 17, 2021

Cyclica\xe2\x80\x99s platform uses a proteome-wide lens to evaluate multiple novel and rare on- and off-target interactions simultaneously.

Key Points:

Cyclica\xe2\x80\x99s platform uses a proteome-wide lens to evaluate multiple novel and rare on- and off-target interactions simultaneously.
\xe2\x80\x9cCyclica is building one of the largest and most diversified portfolios of drug discovery programs across therapeutically rich and diverse areas.
PrecisionLife operates an innovation engine that translates proprietary disease biology insights into new drug discovery programs, more successful and cost-effective clinical trials and more personalized clinical decision support tools.\nFrom molecule to medicine, Cyclica embraces the complexity of disease.
With deep roots in the industry, a first-in-class platform, and an innovative decentralized partnership model, Cyclica is creating medicines with greater precision for unmet patient needs.

Cyclica Teams Up with Top-Tier Academic Institutions to Identify a Repurposed COVID Drug

Retrieved on:

Wednesday, April 14, 2021

Research, Infectious diseases, Biotechnology, Health, University, Pharmaceutical, Science, Education, Oncology, Cyclica, Larentiinae, Capmatinib, Drugs, Clinical medicine

b"Cyclica , the partner of choice for data driven drug discovery, in connection with leading Canadian research institutions, has predicted a repurposing drug, capmatinib, with evidence that it attenuates the impact of coronavirus.

Key Points:

b"Cyclica , the partner of choice for data driven drug discovery, in connection with leading Canadian research institutions, has predicted a repurposing drug, capmatinib, with evidence that it attenuates the impact of coronavirus.
\xe2\x80\x9cOur business model has always relied on tight collaboration with partner institutions, accelerated by our AI drug discovery platform.
To learn more about Cyclica\xe2\x80\x99s drug discovery platform, please visit https://www.cyclicarx.com/ .\nFrom Molecule to medicine, Cyclica embraces the complexity of disease.
To learn more about Cyclica and how we partner, please visit www.cyclicarx.com\nRyerson University is Canada's leader in innovative, career-oriented education.

Cyclica Collaborates With Enamine to Use REAL Technology in Its Ligand Design Platform for AI-augmented Drug Design

Retrieved on:

Tuesday, November 5, 2019

Health, Technology, Software, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Pharmaceutical sciences, Health, Cyclica, Larentiinae, Drug discovery, Pharmaceutical industry, LinkedIn, Enamine, Biotechnology, Cyclica, Enamine

At least 80% of these compounds will be synthesized by Enamine within only 3-4 weeks.

Key Points:

At least 80% of these compounds will be synthesized by Enamine within only 3-4 weeks.
For updates on the status of the AI-driven drug discovery platform, follow Cyclica on LinkedIn and Twitter @Cyclica.
Cyclica is a Toronto-based, globally recognized biotechnology company that leverages AI and computational biophysics to reshape drug discovery.
Cyclica provides the pharmaceutical industry with an integrated and end-to-end enabling drug discovery platform focused on polypharmacology.

Cyclica Announces the Integration of the POEM Machine Learning Predictive Engine in their Ligand Express® Platform

Retrieved on:

Friday, May 17, 2019

Technology, Software, Health, Biotechnology, Pharmaceutical, Research, Science, Natural sciences, Biology, Cyclica, Larentiinae, Biotechnology, Ligand, Life sciences

Cyclica, a leading biotechnology company that leverages artificial intelligence and computational biophysics to enable the discovery of new medicines, has announced the addition of a machine learning predictive engine called POEM to its Ligand Express platform.

Key Points:

Cyclica, a leading biotechnology company that leverages artificial intelligence and computational biophysics to enable the discovery of new medicines, has announced the addition of a machine learning predictive engine called POEM to its Ligand Express platform.
With the integration of POEM, Ligand Express now offers insights into the pharmacokinetic properties of small molecules, providing a better understanding of the predicted behaviour of potential drug molecules.
Enabling more effective drug discovery through an integrated computational platform is a central tenant at Cyclica, said Naheed Kurji, President & CEO of Cyclica.
The integration of POEM into Ligand Express further demonstrates Cyclicas commitment to accelerating pharma R&D, and making drug discovery faster, cheaper, and safer.